Chart
Markets
News
Screeners
Community
More

Markets US Stocks Health Technology Biotechnology

Moderna, Inc MRNA

MRNA

NASDAQ

MRNA

Moderna, Inc

NASDAQ

See more on advanced chart See more on advanced chart

No trades

Upcoming Earnings

EPS

Market Cap

Div Yield

P/E

Upcoming Earnings

EPS

Market Cap

Div Yield

P/E

See more on advanced chart See more on advanced chart

Overview

Timeline News Ideas Financials Technicals

MRNA Chart

Trade MRNA with trusted brokers on TradingView Open account

Ideas

MRNA

, 1W

hitendravasudeo

Underperforming stock considering market fall and participation of the fall. Relatively Under performer. testing 78.6% retracement looks to be on charts. 114-100 key support levels to stall the fall. If recovery happen at the support good. RSI hitting oversold on weekly chart as shown will be critical along support support 114-110. If the recovery has to...

$MRNA Intraday

MRNA

, 15Long

KFS_ Pro+

Big giza target up in here \m/ /\ / \ / \ / \ / \ ...

Sunday Prep 9/5 - $MRNA Looking good for a move back to ATH

MRNA

, 240Long

TrueTraderOfficial Premium

The setup is there to take this name back to ATHs. Technically needs over 418.44 to confirm the long trigger, but don’t think that’s going to be a problem if the momentum continues. Will need to see some retests of key levels hold before being interested. First area of interest would be the recent breakout level of $414, but would much prefer a retest of $400/20d.

MRNA Analysis

MRNA

, 1D

No2Office

NASDAQ:MRNA

Buy Moderna with Sl of 129 for target 144/157

MRNA

, 60Long

shashankpt Pro

Buy Moderna with Sl of 129 for target 144/157

Moderna target 250-300. buy @ 175-185

MRNA

, 1DLong

uniproadvisory

Strong buy

MRNA 1H 2/10/2021

MRNA

, 60Long

TheWhiteRider Pro+

MRNA 1H 2/10/2021

buy @ 165-175 .target 250-300

MRNA

, 1DLong

uniproadvisory

buy on dip

Deviation from balance .

MRNA

, 240Long

Lavin123 Pro

Long

Technicals

Analyst rating

Financials

Valuation

Enterprise Value/EBITDA, TTM —

Enterprise Value, FQ —

Market Cap — Basic —

Number of Employees —

Number of Shareholders —

Price/Earnings, TTM —

Price/Revenue, TTM —

Price/Book Ratio, FY —

Price/Sales Ratio, FY —

Balance Sheet

Current Ratio, FQ —

Debt to Equity, FQ —

Net Debt, FQ —

Quick Ratio, FQ —

Total Assets, FQ —

Total Debt, FQ —

Operating Metrics

Return on Assets, TTM —

Return on Equity, TTM —

Return on Invested Capital, TTM —

Revenue per Employee, TTM —

Price History

Average Volume (10 day) —

Beta - 1 Year —

Price - 52 Week High —

Price - 52 Week Low —

Dividends

Dividends Paid, FY —

Dividends per Share, FY —

Expected Annual Dividends —

Dividends Yield —

Margins

Net Margin, TTM —

Gross Margin, TTM —

Operating Margin, TTM —

Pretax Margin, TTM —

Income Statement

Basic EPS, Net Income —

Earnings per Share, Basic, TTM —

EBITDA, TTM —

Gross Profit, FY —

Last Annual EPS —

Last Annual Revenue, FY —

Net Income, FY —

Total Revenue, FY —

Free Cash Flow, TTM —

More financials

Profile

Sector: Health Technology

Industry: Biotechnology

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.